Recombinant chimeric anti-EGFR monoclonal antibody (Zhejiang Xinwei Shengke Biotechnology)
重组抗EGFR人鼠嵌合单克隆抗体（浙江新维盛科生物）
Report date: 2022/01/14 13:23:58
Base Information
Drug NameRecombinant chimeric anti-EGFR monoclonal antibody (Zhejiang Xinwei Shengke Biotechnology)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang Xinweishengke Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesZhejiang Xinweishengke Biotechnology Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A